cyrilzakka/clinical-trials huggingface dataset:
The Predictors of Depression and Burnout Among Surgical Residents: A Cross-sectional Study From Kuwait

To assess the prevalence and risk factors for depression and burnout among residents across surgical specialties in Kuwait.

This is a questionnaire based cross-sectional study conducted in Kuwait from jan 2021- February 2021 An online questionnaire was sent to the residents enrolled to the surgical residency programs in Kuwait. Residency training in Kuwait provides programs in both medical and surgical specialties. Specialties included in our cohort were: general surgery, orthopedic surgery, urology, neurosurgery, Obstetrics and Gynecology and otolaryngology.

The email sent to our participants included an invitation letter detailing the reason behind the questionnaire and that it is confidential and anonymous. Consent was obtained from participants.

Variables:

Variables collected included; age, gender, marital status, smoking history, exercise, specialty, year of training, on-call frequency, assessment of burnout and assessment of depression symptoms.

Eligibility Criteria:
Inclusion Criteria:

- residents enrolled in surgical training in Kuwait. Across all surgical specialties From R1-R5

Exclusion Criteria:

Recently accepted candidates that have not yet started residency.
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

The purpose of the study is to evaluate the change in cognitive ability and activities of daily living in patients with Alzheimer's disease (AD) as measured by specific evaluations during 18 months of dosing.

This trial is a phase 3, multicenter, randomized, double-blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of MPC-7869 to placebo. The study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may be taking approved medication for Alzheimer's disease provided the dose has been stable for at least 6 months.

The primary objective of the study is to evaluate the change in cognition and activities of daily living.

Eligibility Criteria:
Inclusion Criteria:

* Have had a diagnosis of probable Alzheimer's disease.
* Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).
* Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
* Ability to read and understand English or Spanish to ensure compliance with cognitive testing and study visit procedures.
* Female subjects must be surgically sterile or postmenopausal for \> 1 year.
* Subjects currently taking approved medication for Alzheimer's disease for at least six months prior to day 1 may be enrolled.
* Subjects must have a reliable caregiver who can read, understand and speak English or Spanish.

Exclusion Criteria:

* Current evidence of other causes of dementia.
* History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
* Chronic or acute renal, hepatic or metabolic disorder.
* Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.
* Major surgery and related complications not resolved within 12 weeks prior to Day 1.
Platelet Transfusion in Acute-on Chronic Liver Failure

Acute on-chronic liver failure (ACLF) is a severe liver disease with a 28-day mortality rate of up to 40%. When the patients get 3 or more organ failures, the 28-day mortality rate is up to 82.6%. Though the ACLF patients have high short-term mortality, and the only effective treatment method is liver transplantation. However, few patients can be treated due to the scarcity of liver source, rapid disease progression and short transplantation window.

Our team evaluated the platelet function of 100 patients with ACLF by using the thromboelastograghy (TEG 5000). It was found for the first time that the reactivity of platelets of ACLF patients decreased, and the platelet inhibition rate (especially the ADP pathway) was related to patients'short-term prognosis. When the ADP inhibition rate was 70%, the patients'28-day mortality was up to 100%. However, the mechanism of low platelet response to ADP in ACLF patients is still unclear. We found that the platelet function in patients with ACLF 2-3 grade and inhibition rate beyond 70% was improved and the 28-day mortality decreased after platelet transfusion. Whether platelet transfusion can prolong survival time needs to be determined in a prospective controlled study. Therefore, this study is expected to find a new therapeutic method to reduce the mortality of patients with ACLF.


Eligibility Criteria:
Inclusion Criteria:

* 18-60 years old;
* Patients with compensated cirrhosis conformed to the (ACLF) diagnostic criteria of chronic and acute liver failure defined by the European Association of Hepatology (EASL-CLIF), and met the ACLF-2 and 3 grades.

ADP inhibition rate ≥ 70%.

Exclusion Criteria:

* Patients with severe platelet allergy in the past;
* Coma caused by cerebral hemorrhage or primary diseases of the nervous system;
* Those who have taken anti-platelet drugs or anticoagulants within four weeks;
* Rupture and bleeding of EVB occurred within 1 week.
* Those who received platelet transfusion within 1 week;
* Patients with liver cancer or other malignant tumors;
* Pregnant and lactating women;
* Complicated with other serious chronic diseases;
* Not signing the informed consent form;
* Other researchers do not consider it appropriate to participate in the study.
Trial of Tomotherapy in Breast Cancer

Tomotherapy is a new radiation therapy system that uses an integrated CT scanner during delivery of radiation treatment to improve the accuracy of the treatment. Furthermore the irradiation is delivered helicoidally allowing highly conformal shaping of dose distribution. However the magnitude of the clinical advantage of using the system in breast cancer is unknown. The purpose of the present study is to investigate whether or not the Tomotherapy can substantially reduce pulmonary and cardiac toxicities, as compared with conventional radiotherapy.

Prior to surgery: histological confirmation; medical imaging.

Localizing markers are placed in case of breast conserving surgery.

After surgery, patients are randomized to one of two treatment arms:

* Arm I: radiotherapy using tangential chest fields, and supraclavicular field in case of nodal involvement, according to our hospital's standard procedure (Voordeckers M et al, Radiother Oncol 2003;68:227 and 2004;70:225). Dose-fractionation: 50 Gy in 25 fractions over 5 weeks, 2 Gy/fraction. Additional boost 16 Gy in 8 fractions over 2 weeks if breast conserving surgery (verify marker/clip localization) and age \<= 70 years.
* Arm II: radiotherapy using the Tomotherapy system. Target area (breast, thorax wall, nodal areas) delimited according to pre-operative imaging and pathological description. Dose-fractionation (adapted from Whelan T et al, JNCI 2002;94:1143): 42 Gy in 15 fractions over 3 weeks, 2.8 Gy/fraction. Simultaneous boost 0.6 Gy/fraction if breast conserving surgery.

Physics quality control is integrated during treatment in both arms.

Radiotherapy begins within 6 weeks after the last breast surgery. Concurrent or sequential adjuvant systemic treatments are allowed. In case of sequential adjuvant treatment with chemotherapy first, radiotherapy begins within 6 weeks after completion of the adjuvant chemotherapy.

Quality of life, arm mobility and edema, pulmonary and heart function are assessed prior to radiotherapy, at 1-3 months after completion of radiotherapy, then yearly.

Eligibility Criteria:
Inclusion Criteria:

* Informed consent
* Histologically proven breast carcinoma
* Stage I or II (T1-3N0 or T1-2N1 M0, AJCC/TNM 6th edition)
* Surgery with clear margins
* Pre-operative medical imaging (at least CT, MRI, and/or PET-scan)

Exclusion Criteria:

* Prior breast or thoracic radiotherapy
* Pregnancy or lactation
* Fertile patients without effective contraception
* Psychiatric or addictive disorders
Clinical Specialty Queue For Gestational Trophoblastic Neoplasia

The aim of this study is to establish a bidirectional cohort study of GTN specific diseases, including 1020 retrospective cases Queue and 1000 prospective cohorts. Based on the clinical collaboration system for gynecological tumors in multiple tertiary hospitals across the country, establish unified criteria for case inclusion and exclusion, and establish a multi center clinical queue for GTN; Collect baseline information of GTN patients, such as age, reproductive history, environmental and social information, genetic related information, physical examination, physicochemical, imaging, and pathological information; Collect biological specimens such as blood/tissue from patients; Collect information related to the diagnosis, treatment plan, human chorionic gonadotropin (hCG) levels, and toxic side effects of patients during the diagnosis and treatment period; After the end of treatment, follow-up blood hCG levels, imaging, fertility status, as well as recurrence and metastasis status, are conducted to track prognosis, thus building a clinical diagnosis and treatment information database, forming a standardized follow-up system for GTN, identifying high-risk factors for GTN chemotherapy resistance, constructing a precise evaluation model for GTN resistance, and providing high-level evidence-based medicine for effectively improving the initial treatment efficacy of GTN.


Eligibility Criteria:
Inclusion Criteria:

* ① Age ≥ 18 years old; ② Patients clinically diagnosed with GTN (including invasive cases) Molar pregnancy, choriocarcinoma, PSTT, ETT); ③ Complete informed consent for enrollment.

Exclusion Criteria:

* ① Having mental illness or cognitive impairment, unable to cooperate in completing the investigation with Patients with concurrent malignant tumors; ③ Participants with severe missing follow-up data.
The Effects of Medicaid Policy Interventions on Racial Equity in Severe Maternal Morbidity

The goal of this study is to learn about the effects of structural inventions, such as equity-focused Medicaid polices, on severe maternal morbidity (SMM) and mortality and maternal health. The main questions it aims to answer are:

1. What is the effect of Medicaid healthcare quality interventions on SMM?
2. What is the effect of Medicaid healthcare quality interventions + doula care?
3. What are Medicaid beneficiaries' experiences in receiving services and the potential impact of integration of doula services and equity practices?

Participants will be asked to describe experiences as a result of structural interventions and focused Medicaid policies.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant and postpartum Medicaid beneficiaries across the US

Qualitative:

* Medicaid beneficiaries who self-identify as Black and/or live in PA Health Equity Zones
* Doulas who provide care to Medicaid beneficiaries in Pennsylvania
* Medicaid Managed Care Organization (MCO) administrators in Pennsylvania. Severe maternal morbidity and mortality outcomes will be assessed in healthcare records and for these quantitative outcomes, patients will not be recruited individually

Exclusion Criteria:

-
Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes

The purpose of this study is to assess whether a cocktail of seven approved drugs (so-called "Basel cocktail") can be used for simultaneous phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.


Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Male aged between 18 and 45 years
* No clinically significant findings on the physical examination
* Body mass index (BMI) between 18 and 28 kg/m2
* Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and heart rate (HR) 45-90 bpm (inclusive)
* 12-lead electrocardiogram (ECG) without clinically relevant abnormalities
* Hematology and clinical chemistry results not deviating from the normal range to a clinically relevant extent
* Negative results from urine drug screen
* Ability to communicate well with the investigator and to understand and comply with the requirements of the study

Exclusion Criteria:

* Known hypersensitivity to any excipients of the drug formulations
* Treatment with another investigational drug within 30 days prior to screening
* History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening
* Excessive caffeine consumption, defined as mor than 800 mg per day
* History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug
* Smoking within the last 3 months prior to screening
* Previous treatment with any prescribed or OTC medications (including herbal medicines such as St John's Wort) within 2 weeks prior to screening
* Loss of 250 ml or more of blood within 3 months prior to screening
* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
* Legal incapacity or limited legal capacity at screening
Safety and Efficacy Between the Distal and Proximal Radial Vascular Access Technique

The investigators are conducting a randomized clinical trial, having as a primary objective, to compare vascular access time between distal and proximal radial approach. Secondary objectives include comparing incidence of distal and proximal radial artery occlusion, at 24 hrs and 30 days. As a tertiary objective investigators will compare the preference of the patients for each access in subsecuent interventional procedures.

Randomised Clinical Trial / Equivalence Model Permutted block asignation 1:1 Statistical Power 90% and Significance 2.5%. Sample Loss estimation - 15% Chi-square to categorical and T Student to numerical variables. Logistic regression binomial for adverse outcomes. If needed, an intention to treat analysis will be performed.

Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years
* Clinical indication for coronary angiography / angioplasty
* Palpable radial and distal radial pulse
* Previous clinical Barbeau test
* Radial and distal radial patency via vascular ultrasound
* 24-hour and 30-day follow-up feasibility

Exclusion Criteria:

* Previous vascular punctions in the studied anatomic site
* Artery introductor relationship
* Arteriovenous fistula
* Current treatment with oral anticoagulants
* Contraindication for Heparin
* Incomplete medical records
* Vascular access sheath - radial artery mismatch
* Distal radial or ulnar fracture history
Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment.

PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma

PRIMARY OBJECTIVES:

I. To determine correlation between 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies.

II. To compare radiotherapy target volume delineation with and without 18F- FDOPA-PET metabolic imaging information to determine role of metabolic imaging in radiotherapy treatment planning.

SECONDARY OBJECTIVES:

I. To determine correlation between concordance of 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies and patient outcomes including overall survival and progression free survival.

OUTLINE:

Beginning at no more than 1 week before biopsy and resection, patients undergo fluorine F 18 fluorodopa-labeled PET/CT scan and pre-operative MRI. Patients then undergo stereotactic craniotomy. Some patients may also undergo radiation therapy.

After completion of study treatment, patients are followed up every year for 5 years.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years.
* MRI findings compatible with newly diagnosed high- or low-grade malignant glioma
* Planned craniotomy and resection or biopsy
* Willing to sign release of information for any radiation and/or follow-up records
* Negative pregnancy test done =\< 48 hours of injection of study drug, for women of childbearing potential only
* Provide informed written consent
* Patients with eGFR \< 60 mg/min/1.72m2 are eligible for the study; PLEASE NOTE: the patient is not eligible to receive the contrast for the pMRI at the study dose.

Exclusion Criteria:

* Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator, kidney failure)
* Unable to undergo an 18F-FDOPA PET scan (e.g. Parkinson's Disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists)
* Pregnant women; nursing women; men or women of childbearing potential who are unwilling to employ adequate contraception
The Influence of Amitriptyline on Learning in a Visual Discrimination Task

The purpose of this study is to determine whether 75 mg amitriptyline affect the sleep dependent consolidation of procedural memory (visual discrimination task, Karni-Sagi-paradigm).

Rapid eye movement (REM) sleep is considered critical to the consolidation of procedural memory - the memory of skills and habits. Many antidepressants strongly suppress REM sleep, however, and procedural memory consolidation has been shown to be impaired in depressed patients on antidepressant therapy. As a result, it is important to determine whether antidepressive therapy can lead to amnestic impairment. We thus investigate the effects of the anticholinergic antidepressant amitriptyline on sleep-dependent memory consolidation in 32 healthy men in a double-blind, placebo-controlled, randomized parallel-group study.

Eligibility Criteria:
Inclusion Criteria:

* male gender
* age 18 through 40 years
* ability to communicate effectively in German

Exclusion Criteria:

* shift work within the past 24 months
* any sleep disorder as measured by the Pittsburgh Sleep Quality Index
* irregular sleep/wake patterns or extreme chronotype as measured by the Morningness-Eveningness Questionnaire
* history of any neurologic or psychiatric disorders
* regular medication intake within the past four weeks
* contraindications for amitriptyline
* abnormal electrocardiogram (ECG)
The Evaluation of the Curative Effect of Electrophysiological Rehabilitation Services on Endometrial Repair After Induced Abortion

Exploring the efficacy evaluation of electrophysiological rehabilitation services in endometrial repair after induced abortion, providing scientific basis for medical institutions and government post abortion care decision-making.

This study is a multicenter randomized controlled intervention study. The main endpoint of the study was the measurement of endometrial thickness by transvaginal ultrasound on days 21-23 after abortion.

Secondary study endpoint:

1. Postoperative uterine contraction pain;
2. Patient satisfaction;
3. Menstrual recurrence time;
4. Changes in menstrual flow for two consecutive periods after surgery;
5. The duration of two consecutive menstrual periods after surgery.


Eligibility Criteria:
Inclusion Criteria:

1. Female aged 18-40 years old;
2. Previous menstrual patterns;
3. Pregnancy duration 6-10 weeks;
4. Ultrasound indicates intrauterine pregnancy;
5. Voluntarily accepting surgical induced abortion with no contraindications for induced abortion;
6. Voluntarily participate in the trial and sign the informed consent form.
7. Patients or their families are able to understand the research protocol and are willing to participate in this study, providing written informed consent.

Exclusion Criteria:

1. Medical abortion patients;
2. Patients with pelvic and abdominal benign and malignant tumors and other systemic diseases; C) Skin problems such as ulceration, infection, and blisters at the treatment site;

d) Patients with missed miscarriage diagnosed clinically; e) Patients with combined uterine fibroids, adenomyosis, and uterine malformations; f) Those who have inserted intrauterine devices (including copper containing intrauterine devices and levonorgestrel containing intrauterine devices); g) Individuals who have had three or more previous induced abortions; h) Clinical diagnosis of thin endometrium; i) Individuals with a history of cesarean section surgery; j) Individuals with severe mental illnesses; k) Researchers determine other situations that are not suitable for participating in this study; l) Patients or their families are unable to understand the conditions and objectives of this study.
Effect of Azilsartan on Aldosterone in Postmenopausal Females

The purpose of the research is to evaluate the effect of azilsartan medoximil on blood pressure and urinary aldosterone levels in postmenopausal females.

The study is a randomized, placebo-controlled trial of post-menopausal females with stage 1 hypertension. The goal is to randomize 40 post-menopausal females with stage 1 hypertension and assess whether azilsartan reduces urinary aldosterone levels. We will compare subjects having azilsartan medoximil (treatment group) with placebo group. Additionally, a small sub-study comparing pre-menopausal and post-menopausal female aldosterone levels was performed as well as the presence of aldosterone production in fat cell cultures of a subset of 3 patients in the randomized trial.

Eligibility Criteria:
Inclusion Criteria:

* Female
* Ages 45-70
* Post-menopause: have not had a menstrual period for one year or more
* Diagnosed with Stage 1 hypertension
* Body Mass Index (BMI) greater than or equal to 28

Exclusion Criteria:

* Male
* Diagnosed with Stage 2 hypertension
* Stage 1 hypertension requiring more than one agent
* Pregnancy or attempting pregnancy
* Use of oral contraceptive pills
* Use of hormone replacement therapy
* Use of steroids
* Stage 3 or greater kidney disease
* Diabetes mellitus
* untreated hypothyroidism or hyperthyroidism
* primary hyperaldosteronism
* Cushing's disease
* obstructive sleep apnea
* chronic illness, e.g. chronic liver disease
* NYHA class III or greater heart failure
* moderate to severe lung disease
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.


Eligibility Criteria:
Inclusion Criteria:

* History of eye allergies within the past 24 months
* Willing to not wear contact lenses at least 72 hours prior to the study start and during the study period

Exclusion Criteria:

* Current eye infection
* Eye surgery within 3 months or vision correction surgery within 6 months
* Any planned surgery during the study or 30 days after the study